Obe-cel for relapsed/​refractory B-ALL: The FELIX study cover art

Obe-cel for relapsed/​refractory B-ALL: The FELIX study

Obe-cel for relapsed/​refractory B-ALL: The FELIX study

Listen for free

View show details

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary

During the ALL Hub Steering Committee meeting in April 2026, Daniel DeAngelo led a discussion on the latest findings from the phase Ib/II FELIX trial (NCT04404660) investigating obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The discussion featured contributions from Ibrahim Aldoss, José María Ribera, André Baruchel, Wendy Stock, and Nicolas Boissel.


This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.